✓ Translated by DotMD AI Clinical Council Source: Journal of the European Academy of Dermatology and Venereology : JEADV • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #35297108 ↗

Phase III Randomized Trial: Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial

Original Paper Title: “Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Fixed-dose combination Cal/BD foam used for long-term management of psoriasis significantly reduces psoriasis-related work productivity and activity impairment which may result in substantial indirect cost savings. Clinical Trial Registration NCT02899962, EudraCT number: 2016-000556-95.
  • Study Design & Sample: Phase III Randomized Trial published in Journal of the European Academy of Dermatology and Venereology : JEADV (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of the European Academy of Dermatology and Venereology : JEADV (2022), this phase iii randomized trial evaluating human clinical outcomes investigated: Psoriasis contributes to unemployment, work impairment, missed workdays and substantial indirect costs due to lost productivity. Key clinical takeaway: Fixed-dose combination Cal/BD foam used for long-term management of psoriasis significantly reduces psoriasis-related work productivity and activity impairment which may result in substantial indirect cost savings. Clinical Trial Registration NCT02899962, EudraCT number: 2016-000556-95.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of the European Academy of Dermatology and Venereology : JEADV, 2022-07-15; Phase III Randomized Trial; Rigor 88/100): Fixed-dose combination Cal/BD foam used for long-term management of psoriasis significantly reduces psoriasis-related work productivity and activity impairment which may result in substantial indirect cost savings. Clinical Trial Registration NCT02899962, EudraCT number: 2016-000556-95.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: bio-combination-28-schuessler-salts → Rx: betamethasone-dipropionate → Rx: betamethasone-valerate-foam → Condition: vitiligo → Condition: warts →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 35297108: Phase III Randomized Trial: Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial

3 of 3 Free Questions Remaining